Melanoma Vaccine (Clinical Trials)

Cancer Vaccine Increases Survival Rate for Melanoma Patients

Published in Vaccine Weekly, November 10th, 1997

Avax Technologies, Inc., Kansas City, Missouri, announced the company has initiated a Phase III clinical trial for M-Vax, a therapeutic vaccine for melanoma based on the company's core AC Vaccine technology.

The company and its researchers believe this to be the first therapeutic cancer vaccine to show a substantial increase in the survival rate for patients with stage 3 melanoma.

The announcement follows the company's earlier meeting with officials from the Center for Biologics Evaluation and Research of the U.S. Food and Drug Administration (FDA). Following this meeting to discuss the proposed Phase III clinical trial, the company has moved...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1997-11-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry